ElaCor

ElaCor is a clinical-stage medical device company focused on developing novel transcatheter therapies for patients suffering from heart failure. The company's primary focus is on Heart Failure with Preserved Ejection Fraction (HFpEF), a condition with significant unmet medical needs and few effective treatment options. ElaCor's lead product is a percutaneous device designed to reduce elevated left atrial pressure, thereby improving symptoms and clinical outcomes. The company has received FDA Breakthrough Device Designation for its innovative approach to cardiac hemodynamic management. Headquartered in Columbus, Ohio, ElaCor is led by a team of experts in cardiovascular medicine and medical device engineering. The company is currently advancing its technology through early-stage clinical trials to demonstrate safety and efficacy in heart failure populations.